Ralf Schmid
Chief Financial Officer
Ralf Schmid is the Chief Financial Officer of F2G. He brings more than 20 years of experience in M&A, licensing, and public and private market transactions in various leading positions in the fields of finance and administration in biotechnology and at several multinational companies, including Sandoz. Ralf joined F2G in 2016 from Nabriva Therapeutics AG, where he had served on the management board since the company’s spin-off from Sandoz in 2006. In his role as Chief Financial Officer and Chief Operating Officer, Ralf was instrumental in taking the company public on Nasdaq in 2015.
Ralf holds a master’s degree in finance and economics from Otto-Friedrich-Universität Bamberg, Germany.